The necessity of a central asset listing is made clear when considering there are 10,700 rare diseases -- and tens of thousands of compounds with therapeutic potential.


bioXcross will serve as a logical first stop for orphan asset search. It is not a subscription service, but a free site open to all industry actors for maximum information exchange. This unique tool should accomplish in a single day what presently can take weeks.

bioXcross -- [Coming Soon]

The New M&A Model - From “One to One” to “Many to Many.”

With a tens of thousands of diseases, compounds, and participants a central forum is needed to rationalize orphan asset transactions.

To optimize their opportunities, firms must have access to the widest range of assets.

The necessity of a central asset listing is made clear when considering there are 10,700 rare diseases -- and tens of thousands of compounds with therapeutic potential.

In seeking acquisitions, partners, or buyers, biopharmas would benefit by not being limited to conventional approaches, but a more comprehensive and systematic approach - bioXcross.

More than 75% of biopharmas that achieve success will do so by selling out to a larger firm. Right now management has limited control of the end game once it puts itself in the hands of an investment bank with companies shown on average to only three potential buyers. However, a firm seeking a buyer on its own for a significant asset or the entire company is not practical in the present environment. Management risks increased exposure to shareholder litigation – especially in the absence of an investment bank valuation. With bioXcross, a firm can anonymously solicit bids from the widest possible list of buyers while keeping the process in its own hands for as long as possible.

Biopharmas will ultimately derive full benefit when a central information exchange is mated with an auction process exposing an asset to bidding from all interested parties.

Listing on bioXcross is:

1. Free of charge.

2. Has virtually unlimited space.

3. May remain as long as the registrant wishes.

4. A registrant may list multiple assets and/or services. Registrants are welcome to list whatever assets they wish to sell, partner, or purchase downloading as much relevant information as needed.

5. Individual executives, scientists, and clinicians are welcome to list their resumes and employment goals on bioXcross pages that will also be available free of charge.

6. Provides the basis for competitive bidding to determine the true market price of an asset.

bioXcross will serve as a logical first stop for orphan asset search. It is not a subscription service, but a free site open to all industry actors for maximum information exchange. This unique tool should accomplish in a single day what presently can take weeks.